On December 21, Sanofi announced the termination of the global clinical development program for tusamitamab ravtansine (SAR408701, IBI-126).The decision is mainly based on the second-line of this product.Treatment of CEACAM5 PositiveInterim analysis data from the Phase III CARMEN-LC03 study in metastatic non-squamous non-small cell lung cancer (nsqNSCLC).The results showed,AndCompared with docetaxel, tusamitamab ravtansine as a monotherapy showed an improved trend in overall survival (OS) but did not meet the dual primary endpoint of progression-free survival (PFS).Tusamitamab ravtansine is an antibody-drug conjugate (ADC) targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). CEACAM5 is a cell surface glycoprotein that is highly expressed in non-small cell lung cancer, gastric cancer, and other cancers.In August 2022, Innovent Biologics and Sanofi entered into a strategic collaboration in the oncology field, which includes the introduction of tusamitamab ravtansine for clinical development and exclusive commercialization rights in China. According to the agreement terms, Sanofi is entitled to receive potential milestone payments of up to 80 million euros in total, as well as royalties based on net sales after the product receives regulatory approval and is launched in China.Currently, Innovent is conductingOnetusamitamab ravtansineIn combination with Sintilimab andtusamitamab ravtansineCombination of Sintilimab + Platinum-based Chemotherapy + Pemetrexed for CEACAM5-positive ExpressionnsqNSCLC PatientsIPhase I Study (CTR20231237)。Sanofi stated that it will continue to explore the potential of ADC and CEACAM5-targeted research based on the tusamitamab antibody in several types of cancer. According to the PharmaCube database, Sanofi also has a CEACAM5 ADC product, SGN-CEACAM5C, co-developed with Seagen, currently undergoing Phase I clinical trials for solid tumors.Copyright © 2023 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
